
    
      Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over
      the course of approximately 9 weeks. Qualified subjects are randomized 1:1:1 to receive
      either High Dose SkQ1 ophthalmic solution, Low Dose SkQ1 ophthalmic solution, or Placebo
      (vehicle of SkQ1 ophthalmic solution).

      The Primary Endpoints are:

      Change from Baseline (Visit 2) to Visit 5 in Corneal Fluorescein Staining;

      Change from Baseline (Visit 2) to Visit 5 in Grittiness Symptom
    
  